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OBJECTIVES: Large, nationally-representative data sources of epidemiological and
health outcome information are scarce in Japan. The aim of this study was to
assess the evidence for validity of a national patient-reported survey of the adult
Japanese population comparedwith existing population-based studies.METHODS:
The data source for this comparison was the 2010 Japan National Health andWell-
ness Survey (NHWS) (N25,000). The NHWS is a self-reported, Internet-based sur-
vey administered to the adult population of Japan. A random stratified sampling
framework was implemented, with age and gender strata, to ensure the final
NHWS sample was identical to the demographic composition of the Japanese pop-
ulation. Sampling weights were applied to all analyses to project to the entire
country’s population. Prevalence statistics generated from NHWS were then com-
pared with existing epidemiological information obtained through literature
reviews. RESULTS: For certain conditions defined by clinical measures that pa-
tients may not be aware of (e.g. COPD), large differences in prevalence between
NHWS (COPD  1.37%) and the literature (10.9% reported airflow limitations in
Fukuchi et al., 2004) were observed. In these cases, differences generally disap-
peared when analyses focused purely on prevalence of awareness of diagnosis
(NHWS 1.37% vs. Fukuchi et al., 2004: 1.02%). Though some differences were ob-
served, most other conditions were generally similar between NHWS and the lit-
erature (e.g., atrial fibrillation: 0.73% vs. 0.56%, respectively; asthma: 2.55% vs.
3.40%, respectively). CONCLUSIONS: Although population-level data in Japan are
scarce, patient-reported data can provide useful epidemiological estimates as well
as valuable health outcome data across a variety of conditions. In many instances,
NHWS prevalence rates were comparable to other sources though, because the
NHWS is purely self-report, it provides a perspective based on awareness of diag-
nosis, whichmay not be relevant for all disease. Further comparisons between the
NHWS and other population-based studies are warranted.
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OBJECTIVES: National statistics on the epidemiology and health outcomes associ-
ated with various conditions are difficult to obtain in China. The aim of this study
was to assess the evidence for validity of a patient-reported survey compared with
existing epidemiological data on prominent chronic conditions. METHODS: The
data source for this comparison was the 2010 China National Health andWellness
Survey (NHWS) (N19,954). The NHWS is a self-reported survey administered to
the adult population of urban China using a mixed methodology (an Internet sur-
vey and computer assisted web interviews). A random stratified sampling frame-
work was implemented to ensure the final NHWS sample was identical to the
demographic composition of the urban China population. Horvitz-Thompson sam-
plingweights were applied to all analyses to project to the entire urban population.
Existing epidemiological information was obtained through literature reviews.
RESULTS: A prior systematic review of rheumatoid arthritis across China esti-
mated the pooled prevalence across 41 studies at 0.37%. The NHWS estimated the
prevalence in urban China at 2.14%. A population-based study conducted in 2001-2
using objective clinical measures (fasting blood glucose test and oral glucose tol-
erance test), estimated the prevalence of type 2 diabetes (T2D) at 6.1%, with 2.1%
having been diagnosed. The NHWS estimated the diagnosed prevalence of T2D at
2.95%. Other conditions were generally similar between NHWS and the literature.
CONCLUSIONS: These results suggest that a self-reported patient survey can pro-
vide useful information about the urban Chinese population. The reliance on self-
report underestimates conditions defined by clinical measures that the patient
may not be aware of (e.g., diabetes, COPD) and may result in measurement error
due tomedical illiteracy (rheumatoid arthritis versus osteoarthritis) but has shown
consistency with other population studies that analyzed awareness of the condi-
tion. Further comparisons between the NHWS and other population studies are
warranted.
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OBJECTIVES: Created in 2002, the Patient-Reported Outcome and Quality of Life
Instruments database (PROQOLID) provides a detailed description of 713 generic or
disease-specific assessment tools on the Internet (www.proqolid.org). The objec-
tive of this study is to identify the PRO instruments available for use in Taiwan.
METHODS: The PROQOLID database was explored using the search engine and
selecting in the field language the key words “Chinese for Taiwan.” RESULTS: For-
ty-four questionnaireswere identified representing 6.17% of the instruments avail-
able in PROQOLID. Out of these 44 questionnaires, six were generic (e.g., Duke
Health Profile, Euroqol EQ-5D, Psychosocial Impact of Assistive Device Scale, Fer-
rans and Powers Quality of Life Index, SF-12 Health Survey, and SF-36 Health Sur-
vey). Fourteen different therapeutic areas were identified (e.g., endocrine, system
diseases, neoplasms, respiratory tract diseases, nervous system diseases, or psy-
chiatric disorders), representing 33 different indications. Only two questionnaires
were available for pediatric use (i.e., the Pediatric Quality of Life Inventory Diabetes
Module and the Pediatric Quality of Life Inventory CancerModule). Asthmawas the
most frequent indication (four questionnaires available), followed by diabetesmel-
litus (three questionnaires), Benign Prostatic Hyperplasia (BPH) (two question-
naires) erectile dysfunction (two questionnaires) and Pain (two questionnaires).
Within the therapeutic area of neoplasms, four different indications were identi-
fied (breast, cervix, lung, and ovary). Only one instrument was available for use in
Parkinson’s disease (Parkinson’s Disease Questionnaire – PDQ-39), and one for use
in Alzheimer’s disease (Clinical Dementia Rating). Not a single instrument was
identified in therapeutic areas such as bacterial infections, eye diseases, virus dis-
eases (e.g., AIDS) or otorhinolaryngologic diseases (e.g., rhinitis). CONCLUSIONS:
Results of this overview show that PRO instruments available for use in Taiwan
cover awide variety of indications. Some therapeutic areas, however, are either not
very well represented (e.g., pediatrics or nervous diseases) or not at all (e.g., infec-
tious diseases).
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OBJECTIVES: According to the Principles on Drug Reimbursement Price Approval(P-
DRPA) issued by the Bureau of National Health Insurance (BNHI) Taiwan, in the
submission of new drug application to Pharmaceutical Benefit Scheme, MTC anal-
yse of several clinical trials could be used to assess comparative effectiveness of the
new drug to the currently best treatment(s), with or without the studies directly
compared the treatments. Quality of the MTC analysis should be evaluated in a
structured way in order to digest the potentially complex analysis.METHODS:We
identify the critical points that would have impact on the validity and consistency
of the MTC analysis by reviewing the published papers of methodology of indirect
comparison of clinical trials. RESULTS: The following checking points were pro-
posed: 1) Check the analysis aim and quality of systematic review, including: topic
(patient, intervention, comparator, outcome, PICO), systematic searching for com-
pleteness of all relevant studies included, and quality of included studies and
extracted data; 2) Check the analysis method and the included materials, includ-
ing: the framework of comparison; statistical method; identify in each pair of com-
parison the number of trials included; the important characteristics of each pair of
comparison; and meta-analysis result of each comparison pair including the syn-
thesized effect and heterogeneity; and 3) Check the analysis results, including:
reanalyze the data with the proposed model; check the consistency between indi-
rect evidence and direct evidence if available; check the sensitivity by constructing
the comparison framework from simple (limited comparisons) to complex (all
comparisons) or including additional study characteristics; check the results using
different statistical models and different effect measurements (such as risk ratio,
risk difference, odds ratio etc.). CONCLUSIONS:MTC is a relatively new but poten-
tially valuable method to analyze evidence for comparing effectiveness of several
interventions. Experience of using the structural checking points will be built up.
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OBJECTIVES: Post-marketing surveillance for adverse effects has become an essen-
tial element of new drug andmedical devices development in the European Union
and the USA. The objective of this study is to present an overview of the content of
a database gathering details of Post-Marketing Requirements (PMRs), i.e., studies
requested by the following regulatory agencies: EuropeanMedicines Agency (EMA,
EU), the Food andDrugAdministration (FDA, USA), and theHaute Autorité de Santé
(HAS, France). METHODS: All drug approvals published by the EMA, the FDA, and
the HAS between January 1, 2005 and December 31, 2011 were reviewed to retrieve
PMRs. The information was categorized as follows: product description (brand
name, INN, indication, etc.), application details, PMR details, and information
source. RESULTS: For the FDA, we reviewed 763 original approvals and 944 supple-
ments and included, respectively, 201 and 110 drugs approved with PMRs. For the
EMA, we reviewed 349 marketing authorizations and included 38 files with PMRs.
For theHAS, 3674 opinionswere publishedwith only 174 opinionswith PMRs.Many
HAS requests were long-term follow-up studies. About 43% of the PMRs requested
by the FDA were pediatric studies. At present, the EMA also requires pediatric
studies but under a Pediatric Investigation Plan (PIP). Since 2005, 21 PIPs have been
requested. Nomatterwhich agency is reviewed, all kinds of indications are covered
by the PMRs, e.g., treatment of sepsis, asthma, malaria, depressive disorder, etc.
CONCLUSIONS: This project will be a unique source of centralized information
about PMRs requested in Europe and in the USA. It will be useful to observe the
trends in studies requested, to anticipate the demands, and to integrate the studies
as early as possible in the product development process. The Post-Marketing Re-
quirements database will be available online in an independent website, with ac-
cess by subscription.
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